Company Overview and News
NEW YORK, June 18 — Southeast Asian stock markets fell today, in line with broader Asia as a trade spat intensified between the world’s top two economies.
UOVEF JGSMY ICT SMIVY SVTMF JGS UOVEY SM ICTEF JGSHF U11
The benchmark Philippine Stock Exchange index (PSEi) closed lower yesterday as investors pocketed profits amid recent gains.
ICT JGSMY GTCAP GTCXY NOW JGS BDOUY ICTEF BDOUF PHSXY PSE SPHXF SPHZF JGSHF UVRBF AYAAF PSKXF AYAAY UVRBY SMPH BDO SPHXY URC DNOW ALI
THE RAZON group’s Sureste Properties, Inc. is proposing to build a P308-million dock for cruise ships in Parañaque City, a project that has been elevated to the Office of the President, the Tourism Infrastructure and Enterprise Zone Authority (TIEZA) said Tuesday.
ICT BBRRF ICTEF BLOOM
The Tourism Infrastructure and Enterprise Zone Authority (TIEZA) has submitted to Malacanang a proposal to construct a P308-million Manila cruise port in Paranaque City.
ICT BBRRF ICTEF BLOOM
Philippine stocks slipped as investors stayed on the sidelines a day before the policy meeting of the Bangko Sentral ng Pilipinas (BSP).
ICT PSKXF MPCIY BDOUY ICTEF BDOUF SMPH BDO MPI MPCFF SPHXY PHSXY PSE SPHXF SPHZF
International Container Terminal Services, Inc. (ICTSI) earnings fell 15% on the first three months of 2018 at US$44.1 million from US$51.7 million in the same period the previous year.
INTERNATIONAL Container Terminal Services, Inc. (ICTSI) said its units have signed agreements with Papua New Guinea Maritime Transport Workers Union (PNG MTWU), ahead of the opening of its Motukea International Terminal in Port Moresby, Papua New Guinea in May.
INTERNATIONAL Container Terminal Services, Inc. (ICTSI) is keeping a positive outlook for the year, while being cautious on the impact of the looming trade war between the United States and China on its international operations.
International Container Terminal Services, Inc. (ICTSI) is keeping a positive outlook for the year, while being cautious on the effects of the looming trade war between the United States and China.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET